<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397864</url>
  </required_header>
  <id_info>
    <org_study_id>C1 1412</org_study_id>
    <nct_id>NCT01397864</nct_id>
  </id_info>
  <brief_title>C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks</brief_title>
  <official_title>C1 Inhibitor Treatment Registry to Assess the Safety and Immunological Profile of Ruconest in the Treatment of HAE Attacks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharming Technologies B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients
      treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form
      (Ruconest), to observe adverse events and insufficient efficacy, and to assess the
      immunological profile following single and repeated treatment with Ruconest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see below
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to observe the adverse event profile and insufficient efficacy, following single and repeated treatment with Ruconest or pdC1INHof acute angioedema attacks</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the immunological profile of Ruconest (for suspected hypersensitivity or suspected neutralizing antibodies)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Hereditary Angioedema</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhC1INH or pdC1INH</intervention_name>
    <description>C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)</description>
    <arm_group_label>Hereditary Angioedema</arm_group_label>
    <other_name>Ruconest</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The aim is to recruit 300 patients treated with Ruconest. Additionally, the study will
        continue until 100 patients have been exposed to Ruconest for at least 3 attacks. Enrolment
        in the pdC1INH arm will be unrestricted.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Decision to treat the HAE patient with C1 inhibitor (either Ruconest or pdC1INH)

          -  Patients must give written informed consent

        Exclusion Criteria:

          -  A diagnosis of acquired C1INH deficiency (AAE)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anurag Relan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharming Technologies BV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tessa Heikamp</last_name>
    <phone>+31 71 5247 400</phone>
    <email>t.heikamp@pharming.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UMHAT Alexandrovska EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Staevska, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital by St. Anna Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Hakl, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital A Michallon, CHU Grenoble</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Bouillet, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Maurer, Prof.</last_name>
    </contact>
    <contact_backup>
      <last_name>Markus Magerl, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, 3rd Department of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henriette Farkas, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Cicardi, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PHI University Clinic of Dermatology</name>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vesna Grivcheva-Panovska, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alesund Hospital</name>
      <address>
        <city>Alesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Brudevold, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Pritzier, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Krakow</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystyna Obtulowicz, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bratislava University Hospital</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Hrubiskova, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Martin</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milos Jesenak, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ryhof County Hospital</name>
      <address>
        <city>Jonkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janne Bjorkander, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>HAE</keyword>
  <keyword>Angioedema</keyword>
  <keyword>Recombinant C1 Inhibitor</keyword>
  <keyword>rhC1INH</keyword>
  <keyword>registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

